EXACT Therapeutics AS announces interim results for first half 2023
28 September, 2023: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces its interim results for the first half 2023.
The interim report and presentation for the first half year 2023 are also available on the company's website: www.exact-tx.com. Download pdf here
A presentation of the first half year 2023 followed by a Q&A session will be held today at 14:00-15:00 CET at Carnegie's offices at Aker Brygge, Fjordalleen 16, and through a live webcast.
CEO, Per Walday, CFO, John M. Edminson and CMO, Amir Snapir will hold the presentation. Participants who want to participate in the live webcast or by physical attendance are asked to send an email to anne.myren@carnegie.no.
For more information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com
About EXACT-Tx:
EXACT-Tx is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com
About ACT®:
• ACT is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. • ACT is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
• Initial focus of the Company is oncology, however the ACT platform has potential across therapeutic areas (CNS, immunotherapy) and product classes.
Forward looking statements: This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.